In addition to non-clinical studies, the beneficial effects of modulating TRPV1, TRPA1 and TRPC5 channels in obesity, T2D, atherosclerosis and MS have been investigated in a range of clinical trials. This evidence concerns the gene TRPA1 and obesity disorder.